Back to results
US 2003/0157069 A1Published application
Methods of using flt3-ligand in hematopoietic cell transplantation
AssigneeImmunex Corporation
InventorsStewart D. Lyman, M. Patricia Beckmann
Life of this patent
Estimating the term…
Abstract
Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.
Claims51
A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoletic cell transplant, wherein the Flt3-L composition comprises a polypeptide selected from the group consisting of:
- (i) polypeptides comprising a fragment of amino acids 28-160 of SEQ ID NO:6 that bind Flt3;
- (ii) polypeptides that are least 90% identical to the polypeptides of (i) that retain the capacity to bind Flt3;
- and
- (b) transplanting hematopoietic cells to the patient.
2 more elements
A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant, wherein the Flt3-L composition comprises a polypeptide selected from the group consisting of:
- (i) polypeptides comprising amino acids 28-160 of SEQ ID NO:6 that bind Flt3;
- (ii) polypeptides comprising a fragment of (i) that retain the capacity to bind Flt3;
- and
- (iii) polypeptides that are least 90% identical to the polypeptides of (i) or (ii) that retain the capacity to bind Flt3;
- and
- (b) transplanting hematopoietic cells to the patient.
4 more elements
A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant, wherein the Flt3-L composition comprises a polypeptide selected from the group consisting of:
- (i) polypeptides comprising a fragment of amino acids 28-160 of SEQ ID NO:6 that bind Flt3;
- (ii) polypeptides that are least 90% identical to the polypeptides of (i) that retain the capacity to bind Flt3;
- and
- (b) transplanting hematopoietic stem cells to the patient, wherein the stem cells are autologous stem cells.
2 more elements
A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant, wherein the Flt3-L composition comprises a polypeptide selected from the group consisting of:
- (i) polypeptides comprising a fragment of amino acids 28-160 of SEQ ID NO:6 that bind Flt3;
- (ii) polypeptides that are least 90% identical to the polypeptides of (i) that retain the capacity to bind Flt3;
- and
- (b) transplanting hematopoietic stem cells to the patient, wherein the stem cells are allogeneic stem cells.
2 more elements
A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant, wherein the Flt3-L composition comprises a polypeptide selected from the group consisting of:
- (i) polypeptides comprising a fragment of amino acids 28-160 of SEQ ID NO:6 that bind Flt3;
- (ii) polypeptides that are least 90% identical to the polypeptides of (i) that retain the capacity to bind Flt3;
- (b) administering cytoreductive therapy to the patient;
- and
- (c) transplanting hematopoietic cells to the patient.
3 more elements
A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant, wherein the Flt3-L composition comprises a polypeptide selected from the group consisting of:
- (i) polypeptides comprising a fragment of amino acids 28-160 of SEQ ID NO:6 that bind Flt3;
- (ii) polypeptides that are least 90% identical to the polypeptides of (i) that retain the capacity to bind Flt3;
- and
- (b) administering cytoreductive therapy to the patient;
- and
- (c) transplanting hematopoietic stem cells to the patient, wherein the stem cells are autologous stem cells.
4 more elements
A method, comprising:
- (a) administering a Flt3-L composition to a patient in need of a hematopoietic cell transplant, wherein the Flt3-L composition comprises a polypeptide selected from the group consisting of:
- (i) polypeptides comprising a fragment of amino acids 28-160 of SEQ ID NO:6 that bind Flt3;
- (ii) polypeptides that are least 90% identical to the polypeptides of (i) that retain the capacity to bind Flt3;
- and
- (b) administering cytoreductive therapy to the patient;
- and
- (c) transplanting hematopoietic stem cells to the patient, wherein the stem cells are allogeneic stem cells.
4 more elements
Dependencies are inferred from the claim text.